NASD · Healthcare · Biotechnology · USA
Relay Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Relay Therapeutics is a clinical-stage company developing small molecule therapies for cancer and genetic disease. The company uses its Dynamo platform, which applies computational and experimental approaches to drug proteins previously considered intractable, employing Motion-Based Drug Design methodology. Its lead candidate, zovegalisib, targets PI3Kα mutations in breast cancer and vascular anomalies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Relay Therapeutics Inc stock.
Overvalued: intrinsic value $2.39 per share, market price $17.09, margin of safety -614.7% (as of 2026-10-19).
Its liquidation floor, current assets minus every liability, values the shares at $2.39; the price of $17.09 is 615% above that value.
17 more funds hold it; the full list is part of the paid plan.
104 more in this industry show a wider margin of safety.
RLAY is overvalued (as of the 2026-10-19 close). Its liquidation floor, current assets minus every liability, values the shares at $2.39; the price of $17.09 is 615% above that value.
$2.39 per share (as of the 2026-10-19 close), against a market price of $17.09. That is a margin of safety of -614.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.